Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

1. Open-label, single-arm, prospective pilot study. 2. Definition of advanced non small cell lung cancer: stage IIIb or IV. EGFR mutation status: activating mutation (defined as deletion 19 or exon 21 L858R mutation). 3. Before starting study treatment, computed tomography scans of the chest, B ultrasound of abdomen, 12-lead electrocardiogram, MRI scan of brain, and a bone scan are required. 4. Tumor response, based on investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST v.1.1), will be evaluated every 6 weeks during treatment. 5. Exploratory evaluation will be performed using dynamic contrast enhanced MRI (DCE-MRI). 6. QoL will be assessed using the core module, which will be completed by patients at baseline and before each cycle during treatment. 7. All patients who prematurely discontinue treatment for any reason will be followed for survival.